NmeCas9 is an intrinsically high-fidelity genome editing platform
Nadia Amrani, Xin D. Gao, Pengpeng Liu, Alireza Edraki, Aamir Mir, Raed Ibraheim, Ankit Gupta, Kanae E. Sasaki, Tong Wu, Paul D. Donohoue, Alexander H. Settle, Alexandra M. Lied, Kyle McGovern, Chris K. Fuller, Peter Cameron, , Erik J. Sontheimer
The paper demonstrates that NmeCas9, a Cas9 ortholog, exhibits high-fidelity genome editing in human cells with minimal off-target effects and multiple PAM compatibility.
Genome biology · Dec 1, 2018Peer-reviewedMolecular Biology